Inflammation in irritable bowel syndrome: Myth or new treatment target?

World J Gastroenterol. 2016 Feb 21;22(7):2242-55. doi: 10.3748/wjg.v22.i7.2242.

Abstract

Low-grade intestinal inflammation plays a key role in the pathophysiology of irritable bowel syndrome (IBS), and this role is likely to be multifactorial. The aim of this review was to summarize the evidence on the spectrum of mucosal inflammation in IBS, highlighting the relationship of this inflammation to the pathophysiology of IBS and its connection to clinical practice. We carried out a bibliographic search in Medline and the Cochrane Library for the period of January 1966 to December 2014, focusing on publications describing an interaction between inflammation and IBS. Several evidences demonstrate microscopic and molecular abnormalities in IBS patients. Understanding the mechanisms underlying low-grade inflammation in IBS may help to design clinical trials to test the efficacy and safety of drugs that target this pathophysiologic mechanism.

Keywords: Inflammation; Irritable bowel syndrome; Mast cells; Neuroendocrine cells; Pathology.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Enteritis / drug therapy
  • Enteritis / immunology
  • Enteritis / physiopathology*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Inflammation Mediators / antagonists & inhibitors
  • Inflammation Mediators / immunology
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / immunology
  • Intestinal Mucosa / innervation
  • Intestinal Mucosa / physiopathology*
  • Irritable Bowel Syndrome / drug therapy
  • Irritable Bowel Syndrome / immunology
  • Irritable Bowel Syndrome / physiopathology*
  • Molecular Targeted Therapy

Substances

  • Anti-Inflammatory Agents
  • Gastrointestinal Agents
  • Inflammation Mediators